A5056919832- Asthma and respiratory diseases
- Statistical Methods in Clinical Trials
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Systems, Economic Evaluations, Quality of Life
- Eosinophilic Esophagitis
- Advanced Causal Inference Techniques
- Influenza Virus Research Studies
- Pharmaceutical studies and practices
- Statistical Methods and Bayesian Inference
- Migraine and Headache Studies
- Respiratory viral infections research
- Meta-analysis and systematic reviews
- Drug Solubulity and Delivery Systems
- Herpesvirus Infections and Treatments
- Trigeminal Neuralgia and Treatments
- Pediatric health and respiratory diseases
- Analytical Methods in Pharmaceuticals
- Optimal Experimental Design Methods
- IL-33, ST2, and ILC Pathways
- Statistical Methods and Inference
- Neurological Complications and Syndromes
- Nausea and vomiting management
- Mosquito-borne diseases and control
- Sympathectomy and Hyperhidrosis Treatments
GlaxoSmithKline (United Kingdom)
2012-2022
MRC Biostatistics Unit
2021
GlaxoSmithKline (Germany)
2018
Frimley Park Hospital
2016-2017
GlaxoSmithKline (India)
2014
GlaxoSmithKline (Netherlands)
2013
Wellcome Library
1997-2001
Quest Clinical Research (United States)
2001
Monash University
2001
Foundation for Women’s Wellness
2000
The effectiveness of antiviral therapy in preventing disease progression patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown.
Some patients with severe asthma have frequent exacerbations associated persistent eosinophilic inflammation despite continuous treatment high-dose inhaled glucocorticoids or without oral glucocorticoids.
Many patients with severe asthma require regular treatment oral glucocorticoids despite the use of high-dose inhaled therapy. However, systemic can result in serious and often irreversible adverse effects. Mepolizumab, a humanized monoclonal antibody that binds to inactivates interleukin-5, has been shown reduce exacerbations eosinophilic asthma.
The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release from infected cells, they may also reduce inactivation by respiratory secretions. When administered experimentally directly to tract, has potent antiviral effects. We assessed therapeutic activity in adults with acute influenza.
Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission HSV.We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic HSV-2 susceptible HSV-2. The partners infection were randomly assigned receive either 500 mg valacyclovir once daily or placebo for eight months. partner was evaluated monthly clinical signs symptoms herpes....
The logarithmic (log) transformation is a simple yet controversial step in the analysis of positive continuous data measured on an interval scale. Situations where log indicated will be reviewed. This paper contends that should not classed with other transformations as it has particular advantages. Problems using themselves to decide whether or transform discussed. It recommended transformed analyses frequently preferred untransformed and careful consideration given use at protocol design stage.
The efficacy and safety of zanamivir, administered 2× or 4× daily over 5 days, was evaluated in the treatment influenza infections. A total 1256 patients entered study; 57% those randomized had laboratory-confirmed infection. primary end point, "alleviation major symptoms," created to evaluate differences clinical impact. In overall population with without infection, zanamivir reduced median number days reach this point by 1 day (P = .012 vs. placebo; P .014 placebo). reduction greater...
Background. Influenza infection rates are higher in children than other age groups. This study evaluated the efficacy, safety and tolerability of a 5-day course twice daily inhaled zanamivir, 10 mg, compared with placebo treatment symptomatic influenza A B viral infections among 5 to 12 years age. Methods. double blind, randomized, placebo-controlled, parallel group, multicenter conducted Northern Hemisphere during 1998 1999 season enrolled 471 patients influenza-like symptoms for ≤36 h....
Clinical pharmacology studies were undertaken in young healthy volunteers, a small number of elderly subjects and migraine during between attacks. Absorption after subcutaneous oral administration was rapid. Bioavailability nearly 100% averaged 14% administration. Elimination predominantly by metabolism to non-active indoleacetic acid analogue. The plasma half-lives sumatriptan the metabolite about 2 h. Pharmacokinetic pharmacodynamic variables similar all groups studied not altered presence...
<h3>Background</h3> Successful treatment of influenza depends on an accurate diagnosis the illness and prompt intervention. However, there is a lack data comparing clinical vs laboratory diagnostic techniques. <h3>Objective</h3> To compare community cases with various techniques including multiplex, reverse transcription polymerase chain reaction. <h3>Methods</h3> Clinical diagnosis, viral isolation, hemagglutinin inhibition serology, reaction were used to diagnose in patients enrolled...
Abstract Zanamivir, a potent, highly selective inhibitor of influenza virus A and B neuraminidase, has been evaluated in seven, similarly designed, placebo-controlled studies the treatment influenza. Patients with typical symptoms were recruited when was known to be circulating community. Six these included zanamivir 10 mg inhaled bd (for 5 days) arm, dose regimen submitted regulatory agencies. Pooled analyses conducted evaluate efficacy more precisely terms alleviation population subgroups...
Background: Influenza can cause significant morbidity and mortality, particularly in patients considered to be at high risk (such as the elderly those with chronic disease) of developing influenza-related complications.Data on efficacy zanamivir high-risk are lacking because individual studies recruited a limited number these patients. Methods:A retrospective pooled analysis data from completed before or during 1998-1999 winter season was performed investigate safety inhaled (10 mg twice...
Three oral doses of sumatriptan, 100, 200 and 300 mg, given as dispersible tablets, were compared in the acute treatment migraine a double-blind, placebo-controlled, parallel-group study 1,130 patients from 51 centres eight countries. Patients treated up to three attacks at home over 3-month period recorded results on diary card. Safety follow-ups performed monthly clinic. All sumatriptan significantly (p less than 0.001) more effective placebo relieving headache within 2 h treatment....
The aims were to determine the effect of an oral inhibitor signaling mediator p38 mitogen‐activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers inflammation in chronic obstructive disease (COPD). Three hundred two individuals with GOLD stage II COPD randomized losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 μg/500 μg combination (SFC), or placebo a 12‐week, randomized, double‐blind, double‐dummy study...
Abstract Recurrent events in clinical trials have typically been analysed using either a multiple time‐to‐event method or direct approach based on the distribution of number events. An area application for these methods is exacerbation data from respiratory trials. The different approaches to analysis and issues involved are illustrated large trial (n = 1465) chronic obstructive pulmonary disease (COPD). For rates, interest centres comparison rates each treatment which favours...
Various statistical methods have been used to measure the impact of treatment on chronic obstructive pulmonary disease (COPD) exacerbations. Poisson regression has recently recommended as appropriate method but model does not satisfactorily account for variability between patients. In contrast, use a negative binomial model, which corresponds assuming separate parameter each patient, offers more appealing approach. The present paper reviews analysis methods, with particular focus model. To...
Limited data describe the association between frequency of asthma exacerbations and decline in lung function severe asthma.To determine whether are associated with enhanced function.Changes were analyzed retrospectively using from DREAM MENSA studies mepolizumab intervention patients asthma. Patients either nonsmokers or former smokers. A linear regression model was used to analyze relationship number FEV1 across treatment groups.In a combined post hoc analysis, 57% (n = 572) had no...